Hester Biosciences
- Advice
- Hold
Hester Biosciences Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Hester Biosciences
Start SIPHester Biosciences Investment Rating
-
Master Rating:
-
Hester Biosciences has an operating revenue of Rs. 255.26 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 23% is great, ROE of 15% is good. The company has a debt to equity of 63%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 71 | 72 | 51 | 50 |
| Operating Expenses Qtr Cr | 52 | 56 | 41 | 40 |
| Operating Profit Qtr Cr | 19 | 16 | 9 | 10 |
| Depreciation Qtr Cr | 2 | 2 | 2 | 3 |
| Interest Qtr Cr | 3 | 2 | 1 | 1 |
| Tax Qtr Cr | 4 | 4 | 2 | 2 |
| Net Profit Qtr Cr | 11 | 10 | 5 | 5 |
Hester Biosciences Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 5
- Bearish Moving Average
- ___
- 11
- 20 Day
- 1716.4
- 50 Day
- 1762.05
- 100 Day
- 1833.08
- 200 Day
- 1958.55
- 20 Day
- 1726.59
- 50 Day
- 1764.55
- 100 Day
- 1823.26
- 200 Day
- 1984.23
Hester Biosciences Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 1715.27 |
| Second Resistance | 1752.64 |
| Third Resistance | 1779.62 |
| RSI | 46.66 |
| MFI | 19.7 |
| MACD Single Line | -27.5 |
| MACD | -29.78 |
| Support | |
|---|---|
| First Resistance | 1650.92 |
| Second Resistance | 1623.94 |
| Third Resistance | 1586.57 |
Hester Biosciences Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,351 | 135,606 | 57.68 |
| Week | 5,777 | 389,125 | 67.36 |
| 1 Month | 9,038 | 536,377 | 59.35 |
| 6 Month | 7,098 | 288,520 | 40.65 |
Hester Biosciences Result Highlights
Hester Biosciences Synopsis
NSE-Medical-Ethical Drugs
Hester Biosciences L is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 219.35 Cr. and Equity Capital is Rs. 8.51 Cr. for the Year ended 31/03/2022. Hester Biosciences Ltd. is a Public Limited Listed company incorporated on 29/04/1987 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L99999GJ1987PLC022333 and registration number is 022333.| Market Cap | 1,449 |
| Sales | 244 |
| Shares in Float | 0.39 |
| No of funds | 18 |
| Yield | 0.6 |
| Book Value | 5.38 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | 27 |
| Alpha | -0.13 |
| Beta | 0.4 |
Hester Biosciences
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 53.73% | 53.73% | 53.73% | |
| Mutual Funds | 0.03% | 0.03% | 0.03% | |
| Foreign Portfolio Investors | 0.45% | 0.62% | 0.72% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 32.96% | 32.74% | 32.61% | |
| Others | 12.83% | 12.88% | 12.91% |
Hester Biosciences Management
| Name | Designation |
|---|---|
| Dr. Bhupendra Gandhi | Chairman |
| Mr. Rajiv Gandhi | Managing Director & CEO |
| Ms. Priya Gandhi | Executive Director |
| Mr. Ravin Gandhi | Director |
| Mr. Sanjiv Gandhi | Director |
| Mr. Ashok Bhadakal | Independent Director |
| Mr. Naman Patel | Independent Director |
| Mr. Amit Shukla | Independent Director |
| Mr. Sandhya Patel | Independent Director |
| Mr. Ameet Desai | Independent Director |
| Ms. Nina Gandhi | Alternate Director |
Hester Biosciences Forecast
Price Estimates
Hester Biosciences FAQs
What is Share Price of Hester Biosciences ?
Hester Biosciences share price is ₹1699 As on 22 March, 2023 | 03:02
What is the Market Cap of Hester Biosciences ?
The Market Cap of Hester Biosciences is ₹1445.3 Cr As on 22 March, 2023 | 03:02
What is the P/E ratio of Hester Biosciences ?
The P/E ratio of Hester Biosciences is 48.5 As on 22 March, 2023 | 03:02
What is the PB ratio of Hester Biosciences ?
The PB ratio of Hester Biosciences is 5.4 As on 22 March, 2023 | 03:02